Comment
doi: 10.1136/annrheumdis-2016-209502.
Epub 2016 Mar 31.
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration
Affiliations
- PMID: 27034452
- DOI: 10.1136/annrheumdis-2016-209502
Item in Clipboard
Comment
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration
Ann Rheum Dis.
2016 Jul.
No abstract available
Keywords: Anti-TNF; DMARDs (biologic); Rheumatoid Arthritis.
Comment in
-
Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al.Ann Rheum Dis. 2016 Jul;75(7):e38. doi: 10.1136/annrheumdis-2016-209517. Epub 2016 May 4. Ann Rheum Dis. 2016. PMID: 27147708 No abstract available.
Comment on
-
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.Ann Rheum Dis. 2017 Jan;76(1):51-57. doi: 10.1136/annrheumdis-2015-207588. Epub 2015 Jul 6. Ann Rheum Dis. 2017. PMID: 26150601 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
